Coban Arzu, Matur Zeliha, Hanagasi Hasmet A, Parman Yesim
Department of Neurology, Balikesir University Medical Faculty, Cağiş, Balikesir, Turkey.
Clin Neuropharmacol. 2010 May;33(3):158-60. doi: 10.1097/WNF.0b013e3181d479e0.
Therapeutic use of botulinum toxin type A (BT/A) is well known, effective, and safe. Iatrogenic botulism that presents with generalized weakness, dysphagia, and respiratory distress is a rare but significant complication in BT/A treatment. In this study, we report 4 patients who developed iatrogenic botulism after receiving therapeutic doses of BT/A for spasticity and blepharospasm. One patient was placed in intensive care unit, but consequently, every patient recovered fully. The cause of BT/A as an adverse effect is most likely hematological spread of the toxin.
A型肉毒杆菌毒素(BT/A)的治疗用途广为人知,疗效显著且安全。医源性肉毒中毒表现为全身无力、吞咽困难和呼吸窘迫,是BT/A治疗中一种罕见但严重的并发症。在本研究中,我们报告了4例患者,他们在接受治疗剂量的BT/A治疗痉挛和眼睑痉挛后发生了医源性肉毒中毒。1例患者被送入重症监护病房,但最终所有患者均完全康复。BT/A作为一种不良反应的原因很可能是毒素的血液扩散。